Valuation: Asymchem Laboratories (Tianjin) Co., Ltd.

Market Cap 66.56B 9.93B 8.86B 8.25B 7.51B 14.14B 956B 14.24B 99.7B 38.79B 488B 37.27B 36.46B 1,569B P/E 2026 *
50.2x
P/E 2027 * 37.9x
Enterprise Value 61.89B 9.23B 8.23B 7.67B 6.98B 13.15B 889B 13.24B 92.7B 36.07B 454B 34.65B 33.9B 1,458B EV / Sales 2026 *
7.65x
EV / Sales 2027 * 6.42x
Free-Float
62.13%
Yield 2026 *
0.72%
Yield 2027 * 0.96%
Manager TitleAgeSince
Chief Executive Officer 70 1998-10-06
Chief Executive Officer 49 2022-01-18
President - -
Director TitleAgeSince
Director/Board Member 49 2011-07-17
Chairman 70 1998-10-06
Director/Board Member 65 2011-07-17
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 9.93B
+0.02%-3.52%+36.11%+111.11% 1,019B
-1.21%-6.99%+34.08%+60.96% 617B
+1.12%-0.20%+13.62%+80.24% 464B
-3.30%-6.15%+56.45%+34.69% 356B
+0.93%-1.83%+21.65%+41.43% 333B
+0.12%-4.05%+10.70%+33.53% 267B
-0.89%-5.83%-7.00%+7.91% 244B
-0.01%-3.62%+35.28%+52.02% 218B
-0.08%-4.98%+28.34%+93.61% 179B
Average +0.19%-3.74%+25.47%+57.28% 410.8B
Weighted average by Cap. +0.44%-3.63%+28.50%+68.49%

Financials

2026 *2027 *
Net sales 8.08B 1.21B 1.08B 1B 912M 1.72B 116B 1.73B 12.11B 4.71B 59.27B 4.53B 4.43B 191B 9.68B 1.44B 1.29B 1.2B 1.09B 2.06B 139B 2.07B 14.5B 5.64B 70.95B 5.42B 5.3B 228B
Net income 1.35B 202M 180M 168M 152M 287M 19.41B 289M 2.02B 788M 9.91B 757M 740M 31.85B 1.79B 268M 239M 223M 202M 381M 25.78B 384M 2.69B 1.05B 13.16B 1.01B 983M 42.3B
Net Debt -4.67B -697M -622M -579M -527M -993M -67.13B -1B -7B -2.72B -34.26B -2.62B -2.56B -110B -3.66B -545M -486M -453M -412M -777M -52.51B -782M -5.48B -2.13B -26.8B -2.05B -2B -86.15B
Logo Asymchem Laboratories (Tianjin) Co., Ltd.
Asymchem Laboratories Tianjin Co Ltd is a China-based company mainly engaged in providing one-stop comprehensive services for pharmaceutical outsourcing. The Company's business includes customized research and development and production of small molecule drugs (CDMO), chemical macromolecule CDMO, clinical research services, formulation CDMO, biological macromolecule CDMO, technology output and synthetic biology. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company mainly conducts its business in domestic and foreign markets.
Employees
10,617
Trader
Investor
Global
Quality
ESG MSCI
-